Liraglutide antidiabetic drugs

victoza - liraglutide

Diabetes type 2

All type of patients:  44 trials  - Madsbad (vs Glimepiride) - Seino - Feinglos - LEAD-3 mono 1.2mg (Garber) - LEAD-2 (Nauck) (1.2mg vs placebo) - LEAD-1 SU (1.2 mg vs placebo) - LEAD-4 (1.2mg) - LEAD-5 (vs placebo) - Madsbad (vs placebo) - LEAD-2 (Nauck) (1.2 mg vs glimepiride) - LEAD-5 (vs Glargine) - Pratley 1.2mg - LEADER - LEAD-6 - Seino - Harder - LIBRA - NN2211-1800 - EAGLE - NCT00978393 - NN2211-1571 (Vilsbøll) - NN2211-1799 - NN2211-1796 - NN2211-1701 - NCT01234649 - NN2211-3619 - NN8022-1923 - NN8022-1922 - MK-0431-403 - NN2211-1333 - Pratley 1.8mg - LEAD-3 mono 1.8mg (Garber) - LEAD-4 (1.8mg) - LEAD-1 SU (1.8 mg vs placebo) - LEAD-1 SU (1.8 vs rosiglitazone) - LEAD-2 (Nauck) (1.8 mg vs glimepiride) - LEAD-2 (Nauck) (1.8mg vs placebo) - Kaku 0.6mg - Kaku 0.9mg - LEAD 1 (1.8 vs 1.2) - LEAD 2 (1.8 vs 1.2) - LEAD 4 (1.8 vs 1.2) - Pratley (1.8 vs 1.2) - LEAD-1 SU (1.2 vs rosiglitazone)

liraglutide vs placebo

cardiovascular events by 12% (fully demonstrated)

suggested nephropathy by 20% (not demonstrated)

suggested Cardiovascular death by 21% (not demonstrated)

suggested microvascular events by 15% (not demonstrated)

suggested All cause death by 15% (not demonstrated)

liraglutide 1.2mg vs glimepiride

No demonstrated result

A CHANGER by 225% (harmful effect)

vomiting by 240% (harmful effect)

diarrhoea by 75% (harmful effect)

liraglutide 1.2mg vs glimepiride (add on MET)

No demonstrated result

liraglutide 1.2mg vs placebo (add on MET)

No demonstrated result

vomiting by 2127% (harmful effect)

liraglutide 1.2mg vs placebo (add on SU)

No demonstrated result

A CHANGER by 330% (harmful effect)

liraglutide 1.2mg vs placebo (add on TZD+MET)

No demonstrated result

liraglutide 1.2mg vs rosiflitazone

No demonstrated result

liraglutide 1.2mg vs sitagliptin

No demonstrated result

A CHANGER by 356% (harmful effect)

liraglutide 1.8mg vs exenatide on top MET/SU/MET+SU

No demonstrated result

severe adverse events by 180% (harmful effect)

liraglutide 1.8mg vs glimepiride

No demonstrated result

A CHANGER by 284% (harmful effect)

vomiting by 157% (harmful effect)

diarrhoea by 110% (harmful effect)

liraglutide 1.8mg vs glimepiride (add on MET)

No demonstrated result

liraglutide 1.8mg vs insulin glargine (add on SU+MET)

No demonstrated result

A CHANGER by 976% (harmful effect)

vomiting by 1413% (harmful effect)

diarrhoea by 673% (harmful effect)

liraglutide 1.8mg vs liraglutide 1.2mg

No demonstrated result

liraglutide 1.8mg vs placebo (add on MET)

No demonstrated result

liraglutide 1.8mg vs placebo (add on SU)

No demonstrated result

liraglutide 1.8mg vs placebo (add on SU+MET)

No demonstrated result

A CHANGER by 297% (harmful effect)

diarrhoea by 280% (harmful effect)

liraglutide 1.8mg vs placebo (add on TZD+MET)

No demonstrated result

liraglutide 1.8mg vs sitagliptin

No demonstrated result

A CHANGER by 493% (harmful effect)

vomiting by 134% (harmful effect)

diarrhoea by 151% (harmful effect)

liraglutide other doses vs

No demonstrated result

liraglutide other doses vs glibenclamide

No demonstrated result

liraglutide other doses vs glimepiride

No demonstrated result

suggested all hypoglycemia by 95% (not demonstrated)

liraglutide other doses vs insulin glargine

No demonstrated result

liraglutide other doses vs metformin

No demonstrated result

liraglutide other doses vs placebo

No demonstrated result

liraglutide other doses vs placebo (add on MET)

No demonstrated result

liraglutide other doses vs placebo (add on SU)

No demonstrated result

liraglutide other doses vs placebo (on top SU)

No demonstrated result

liraglutide other doses vs rosiglitazone (add on SU)

No demonstrated result

liraglutide other doses vs sitagliptin (add on MET)

No demonstrated result

See more clinical conditions

Patients inadequately controlled on MET+SU therapy :  3 trials  - LEAD-5 (vs placebo) - LEAD-5 (vs Glargine) - LEAD-6

liraglutide 1.8mg vs exenatide on top MET/SU/MET+SU

No demonstrated result

severe adverse events by 180% (harmful effect)

liraglutide 1.8mg vs insulin glargine (add on SU+MET)

No demonstrated result

A CHANGER by 976% (harmful effect)

vomiting by 1413% (harmful effect)

diarrhoea by 673% (harmful effect)

liraglutide 1.8mg vs placebo (add on SU+MET)

No demonstrated result

A CHANGER by 297% (harmful effect)

diarrhoea by 280% (harmful effect)

Patients inadequately controlled on metformin:  6 trials  - Pratley 1.2mg - NN2211-1799 - MK-0431-403 - Pratley 1.8mg - LEAD-2 (Nauck) (1.8 mg vs glimepiride) - LEAD-2 (Nauck) (1.8mg vs placebo)

liraglutide 1.2mg vs sitagliptin

No demonstrated result

A CHANGER by 356% (harmful effect)

liraglutide 1.8mg vs glimepiride (add on MET)

No demonstrated result

liraglutide 1.8mg vs placebo (add on MET)

No demonstrated result

liraglutide 1.8mg vs sitagliptin

No demonstrated result

A CHANGER by 493% (harmful effect)

vomiting by 134% (harmful effect)

diarrhoea by 151% (harmful effect)

liraglutide other doses vs placebo

No demonstrated result

liraglutide other doses vs sitagliptin (add on MET)

No demonstrated result

Patients inadequately controlled on monotherapy :  13 trials  - LEAD-1 SU (1.2 mg vs placebo) - LEAD-5 (vs placebo) - LEAD-5 (vs Glargine) - Pratley 1.2mg - Seino - NN2211-1799 - NN2211-1701 - MK-0431-403 - Pratley 1.8mg - LEAD-1 SU (1.8 mg vs placebo) - LEAD-1 SU (1.8 vs rosiglitazone) - LEAD-2 (Nauck) (1.8 mg vs glimepiride) - LEAD-2 (Nauck) (1.8mg vs placebo)

liraglutide 1.2mg vs placebo (add on SU)

No demonstrated result

A CHANGER by 330% (harmful effect)

liraglutide 1.2mg vs sitagliptin

No demonstrated result

A CHANGER by 356% (harmful effect)

liraglutide 1.8mg vs glimepiride (add on MET)

No demonstrated result

liraglutide 1.8mg vs insulin glargine (add on SU+MET)

No demonstrated result

A CHANGER by 976% (harmful effect)

vomiting by 1413% (harmful effect)

diarrhoea by 673% (harmful effect)

liraglutide 1.8mg vs placebo (add on MET)

No demonstrated result

liraglutide 1.8mg vs placebo (add on SU)

No demonstrated result

liraglutide 1.8mg vs placebo (add on SU+MET)

No demonstrated result

A CHANGER by 297% (harmful effect)

diarrhoea by 280% (harmful effect)

liraglutide 1.8mg vs sitagliptin

No demonstrated result

A CHANGER by 493% (harmful effect)

vomiting by 134% (harmful effect)

diarrhoea by 151% (harmful effect)

liraglutide other doses vs glibenclamide

No demonstrated result

liraglutide other doses vs placebo

No demonstrated result

liraglutide other doses vs placebo (add on SU)

No demonstrated result

liraglutide other doses vs rosiglitazone (add on SU)

No demonstrated result

liraglutide other doses vs sitagliptin (add on MET)

No demonstrated result

Patients inadequately controlled with insulin:  1 trials  - EAGLE

liraglutide other doses vs insulin glargine

No demonstrated result

Patients with insufficient glycaemic control with bitherapy:  3 trials  - LEAD-4 (1.2mg) - LEAD-6 - LEAD-4 (1.8mg)

liraglutide 1.2mg vs placebo (add on TZD+MET)

No demonstrated result

liraglutide 1.8mg vs exenatide on top MET/SU/MET+SU

No demonstrated result

severe adverse events by 180% (harmful effect)

liraglutide 1.8mg vs placebo (add on TZD+MET)

No demonstrated result

Obesity and overweight

All type of patients:  1 trials  - Astrup (NN8022-1807 )

liraglutide vs placebo

No demonstrated result